CCCC Total Current Assets vs Short Term Debt Analysis
| CCCC Stock | USD 5.00 0.02 0.40% |
C4 TherapeuticsInc financial indicator trend analysis is way more than just evaluating C4 TherapeuticsInc prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether C4 TherapeuticsInc is a good investment. Please check the relationship between C4 TherapeuticsInc Total Current Assets and its Short Term Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.
Total Current Assets vs Short Term Debt
Total Current Assets vs Short Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of C4 TherapeuticsInc Total Current Assets account and Short Term Debt. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between C4 TherapeuticsInc's Total Current Assets and Short Term Debt is 0.54. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of C4 TherapeuticsInc, assuming nothing else is changed. The correlation between historical values of C4 TherapeuticsInc's Total Current Assets and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of C4 TherapeuticsInc are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Total Current Assets i.e., C4 TherapeuticsInc's Total Current Assets and Short Term Debt go up and down completely randomly.
Correlation Coefficient | 0.54 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Short Term Debt
Most indicators from C4 TherapeuticsInc's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into C4 TherapeuticsInc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.At present, C4 TherapeuticsInc's Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 2.13, whereas Selling General Administrative is forecasted to decline to about 27.4 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 1.9M | 3.6M | 7.7M | 8.1M | Interest Income | 387K | 3.6M | 8.6M | 9.0M |
C4 TherapeuticsInc fundamental ratios Correlations
Click cells to compare fundamentals
C4 TherapeuticsInc Account Relationship Matchups
High Positive Relationship
High Negative Relationship
C4 TherapeuticsInc fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 118.3M | 400.1M | 506.8M | 430.8M | 376.5M | 362.8M | |
| Short Long Term Debt Total | 13.7M | 22.9M | 42.9M | 87.2M | 71.0M | 46.2M | |
| Other Current Liab | 6.7M | 9.5M | 13.6M | 2.9M | 20.6M | 21.7M | |
| Total Current Liabilities | 33.6M | 43.9M | 51.2M | 44.5M | 42.8M | 44M | |
| Total Stockholder Equity | (112.0M) | 280.8M | 389.6M | 289.2M | 246.1M | 185.9M | |
| Other Liab | 72.7M | 53.6M | 24.4M | 16.9M | 15.2M | 14.4M | |
| Net Tangible Assets | (112.0M) | 280.8M | 389.6M | 289.2M | 332.6M | 168.9M | |
| Property Plant And Equipment Net | 18.9M | 16.6M | 35.1M | 77.5M | 71.1M | 43.9M | |
| Current Deferred Revenue | 20.7M | 27.6M | 31.8M | 33.5M | 15.5M | 27.2M | |
| Net Debt | (76.8M) | (158.8M) | (33.2M) | 57.4M | (55.6M) | (58.4M) | |
| Retained Earnings | (117.5M) | (183.8M) | (267.7M) | (395.9M) | (528.4M) | (502.0M) | |
| Accounts Payable | 5.4M | 5.7M | 4.5M | 1.2M | 1.4M | 2.6M | |
| Cash | 90.5M | 181.7M | 76.1M | 29.8M | 126.6M | 99.2M | |
| Non Current Assets Total | 21.5M | 19.1M | 181.1M | 143.3M | 105.3M | 90.4M | |
| Cash And Short Term Investments | 90.5M | 371.7M | 309.3M | 337.1M | 253.7M | 256.4M | |
| Net Receivables | 4.6M | 4.5M | 5.7M | 1.5M | 11.8M | 15.3M | |
| Common Stock Shares Outstanding | 43.0M | 43.1M | 46.0M | 48.9M | 49.6M | 45.0M | |
| Liabilities And Stockholders Equity | 118.3M | 400.1M | 506.8M | 430.8M | 376.5M | 362.8M | |
| Non Current Liabilities Total | 196.6M | 75.5M | 65.9M | 97.1M | 87.6M | 96.7M | |
| Capital Lease Obligations | 13.7M | 12.9M | 32.1M | 75.7M | 71.0M | 40.3M | |
| Other Current Assets | 1.6M | 4.8M | 10.7M | 9.9M | 5.7M | 6.2M | |
| Other Stockholder Equity | (105.5M) | 64.5M | 658.1M | 689.3M | 774.6M | 813.3M | |
| Total Liab | 230.2M | 119.3M | 117.2M | 141.6M | 130.3M | 128.7M | |
| Net Invested Capital | (112.0M) | 290.8M | 400.4M | 300.7M | 246.1M | 191.8M | |
| Property Plant And Equipment Gross | 18.9M | 16.6M | 42.0M | 85.6M | 78.9M | 48.1M | |
| Total Current Assets | 96.8M | 381.0M | 325.7M | 287.6M | 271.2M | 272.4M | |
| Accumulated Other Comprehensive Income | (1K) | 13K | (775K) | (4.1M) | (127K) | (133.4K) | |
| Net Working Capital | 63.1M | 337.2M | 274.4M | 243.0M | 228.4M | 228.4M | |
| Short Term Debt | 880K | 1.0M | 1.3M | 7.0M | 5.2M | 3.0M | |
| Property Plant Equipment | 18.9M | 16.6M | 3.1M | 7.4M | 6.7M | 10.6M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether C4 TherapeuticsInc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of C4 TherapeuticsInc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of C4 Therapeuticsinc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on C4 Therapeuticsinc Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.Note that the C4 TherapeuticsInc information on this page should be used as a complementary analysis to other C4 TherapeuticsInc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for CCCC Stock analysis
When running C4 TherapeuticsInc's price analysis, check to measure C4 TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 TherapeuticsInc is operating at the current time. Most of C4 TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of C4 TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 TherapeuticsInc's price. Additionally, you may evaluate how the addition of C4 TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |
Is C4 TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 TherapeuticsInc. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.37) | Revenue Per Share 0.368 | Quarterly Revenue Growth (0.19) | Return On Assets (0.21) | Return On Equity (0.48) |
The market value of C4 TherapeuticsInc is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is C4 TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 TherapeuticsInc's market value can be influenced by many factors that don't directly affect C4 TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between C4 TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.